Medical Devices India

India Wound Care Biologics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

India Wound Care Biologics Market Industry Trends and Forecast to 2034: Segmented by (Product, Wound, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $42.9 Mn Placeholder estimate
Estimate 2025 $47.8 Mn 1.9% of the global market
Projected 2034 $126.2 Mn 164.2% Adds $78.5 Mn over 9 forecast years
CAGR 2025–2034 11.4% Faster than 49% of 186 Medical Devices markets here
Key players 5
  • India is 1.86% of the global market.
  • In APAC, the largest is China at $211.5 Mn.
  • Fastest growing: India (this report) at 11.4% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$78.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Wound Care Biologics Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $42.9 Mn — —
2025 (base) $47.8 Mn +$4.9 Mn —
2026 (forecast) $53.2 Mn +$5.4 Mn +11.4%
2027 (forecast) $59.3 Mn +$6.1 Mn +24.1%
2028 (forecast) $66.1 Mn +$6.8 Mn +38.2%
2029 (forecast) $73.6 Mn +$7.5 Mn +54%
2030 (forecast) $82.0 Mn +$8.4 Mn +71.6%
2031 (forecast) $91.3 Mn +$9.3 Mn +91.1%
2032 (forecast) $101.7 Mn +$10.4 Mn +112.9%
2033 (forecast) $113.3 Mn +$11.6 Mn +137.2%
2034 (forecast) $126.2 Mn +$12.9 Mn +164.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

India Wound Care Biologics Market Analysis at a glance
Market size, 2025$47.8 Mn placeholder estimate
Forecast, 2034$126.2 Mn placeholder estimate
Growth (CAGR), 2025–203411.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, wound and end user (see all)
Key playersOrganogenesis, MiMedx, Smith & Nephew, Integra Life Sciences Corporation, Vericel (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Wound Care Biologics Market Analysis Executive Summary

Wound care biologics use living or natural materials such as skin substitutes and growth factors to heal hard-to-heal wounds.

Key segments of the wound Care Biologics market include product (Skin Substitutes, Growth Factors and Amniotic Membranes) and wound (Diabetic Foot Ulcers, Venous Leg Ulcers and Burns).

Bar chart: India Wound Care Biologics market size, 2024–2034, placeholder estimates. $42.9 Mn in 2024, $47.8 Mn in 2025 and $126.2 Mn in 2034, 11.4% CAGR.
India Wound Care Biologics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Wound Care Biologics Market Dynamics

Market Growth Drivers

More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the wound Care Biologics market.

Opportunity

Ready-to-use formulations, biosimilars and supply security programmes give the wound Care Biologics market room to grow.

Market Restraints

Drug shortages, price controls, generic competition and strict hospital budgets hold back the wound Care Biologics market.

Competitive Landscape for Wound Care Biologics Market in India

The wound Care Biologics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Wound Care Biologics Market in India

Wound Care Biologics in India: rules and payment

Since October 2023, every medical device sold in India needs a licence under the Medical Devices Rules, 2017, from the Central Drugs Standard Control Organisation (CDSCO) or, for some lower-risk devices made in India, a state authority.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how wound Care Biologics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Wound Care Biologics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Wound Care Biologics in context

India compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 12th highest of the 17 countries we cover in APAC.[1]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 13th highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 7.4% of people (2025). World: 10.4% of people (2025). 13th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Wound Care Biologics market in India?
Placeholder estimate: about $47.8 Mn in 2025, rising to about $126.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Wound Care Biologics market in India growing?
Placeholder estimate: about 11.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Wound Care Biologics market report cover?
The report splits the market by product (Skin Substitutes, Growth Factors, Amniotic Membranes, Collagen Products), wound (Diabetic Foot Ulcers, Venous Leg Ulcers, Burns, Pressure Ulcers) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Wound Care Biologics market?
Key players include Organogenesis, MiMedx, Smith & Nephew, Integra Life Sciences Corporation and Vericel.
What is driving the Wound Care Biologics market?
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the wound Care Biologics market.
Who regulates Wound Care Biologics in India?
Since October 2023, every medical device sold in India needs a licence under the Medical Devices Rules, 2017, from the Central Drugs Standard Control Organisation (CDSCO) or, for some lower-risk devices made in India, a state authority. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
How much research is published on Wound Care Biologics?
PubMed lists 8 papers on Wound Care Biologics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in India

See all

Related on wounds and burns and biologics and biosimilars

See the topic